Phase 3 N=93 Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Ocular Hypertension · Glaucoma
Primary: Extent of Exposure — 224.4; 101.8; 314.6 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus
Tinnitus
Primary: Number of Participants With Serious Adverse Events — 1; 2 participants
N/A N=10 PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis
Healthy
Primary: Mean in Cerebral Metabolic Rate of Acetoacetate Before or After 4 Days of Ketogenic Diet — 0.672; 4.83 µmol/100g/min
N/A N=149 Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
Cataract
Primary: Mean Binocular Defocus Visual Acuity (VA) — 0.570; 0.569; 0.404; 0.388 logMAR
N/A N=8 Effect of Gain on Closed-Loop Insulin
Type 1 Diabetes
Primary: Glucose Area Under the Curve (AUC) Breakfast — 66.8; 48.8; 37.4 mmol/l/min — p=0.0011
Phase 3 N=24 Methylphenidate to Improve Balance and Walking in MS
Multiple Sclerosis
Primary: Change From Baseline in Timed Up and Go (TUG) Test Time at 6 Weeks — -0.7; -1.3 change in seconds from basline
N/A N=101 Testosterone Antidepressant Augmentation in Women
Depression
Primary: Depressive Symptom Severity — 15.3; 14.1 units on a scale
Phase 4 N=36 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Type 2 Diabetes
Primary: Percent Change in Fractional Excretion of Sodium (FENA) — 41; -5.0 percentage of change — p==0.012
Phase 3 N=8,651 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Hemorrhagic Fever, Ebola
Primary: Laboratory-confirmed Ebola (Study Diagnostics) — 0; 0 Participants
N/A N=345 A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: 30-Day Person Time Analysis Risk of NAION Associated With PDE5 Inhibitor Use — 2.27 Relative risk of exposure
N/A N=94 Impact of Expanded Peri Operative Warming
Hypothermia · Complications
Primary: Incidence of Hypothermic Events — 5; 10 participants — p=0.12
Phase 4 N=10 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
End-Stage Renal Disease · Hepatitis C
Primary: Number of Participants With Grade 3 or Higher Treatment-related Adverse Events as US Department of Health and Human Services Common Terminology of Adverse Events (CTCAE)…
Phase 3 N=224 Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain
Acute Pain
Primary: Patient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline. — 5.5; 4.5 units on a scale
N/A N=10 Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
Hepatitis B
Primary: Number of Differentially Expressed Genes at p < 0.05 (Without Multiple Testing Correction). — 138; 138; 102; 81 number of genes at p<0.05
N/A N=15 The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
Lung Cancer
Primary: Dose Response — -43.6; -15.1; -32.8; -63.5 percent difference